Compare BioNano Genomics Inc (BNGO) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Snap On Incorporated — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Snap On Incorporated trades at $405.04 (market cap $20.96B). The key difference: Snap On Incorporated is far larger — about 1587.9× BioNano Genomics Inc's market cap, and Snap On Incorporated pays a 2.41% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | SNA | |
|---|---|---|
Market Cap | $13.20M | $20.96B |
Sector | Health | Technology |
52-Week High | $4.92 | $413.62 |
52-Week Low | $1.09 | $313.01 |
Enterprise Value | $15.81M | $20.48B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Snap-on Incorporated (SNA) trades at $401.11, down 0.21% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong profitability with a 19.6% net income margin and ROE of 17.83%, while recent acquisitions like Diesel Laptops for $100 million aim to expand heavy-duty diagnostics capabilities. Q1 2026 earnings missed expectations slightly, but Q2 results are anticipated.
Outlook remains positive with analyst consensus favoring Buy ratings (64.71%) and a $407.50 price target, though risks include margin pressures and muted growth forecasts. The stock offers stability with consistent dividends and share repurchases, but investors should monitor competitive and economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
